全体会议第一场　

时间: Sunday, June 4, 2006 1:00 PM - 4:00 PM
地点: Bldg C, Level 1, Hall C2
主席: James L. Abbruzzese, MD；Gabriel N. Hortobagyi, MD, FACP

Time	Presentation	Speaker
1:00 PM - 4:00 PM	Science of Oncology Award and Lecture 肿瘤科学奖和获奖发言	获奖者： Francis S. Collins, MD, PhD
1:00 PM - 4:00 PM	Partners in Progress Award 合作进步奖	获奖者： Kathy Giusti
1:00 PM - 4:00 PM	Public Service Award 公共服务奖	获奖者： Joseph V. Simone, MD
2:00 PM - 2:15 PM	Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. MP(美法兰＋强的松)联合反应停(THAL)方案一线解救未治疗老年多发性骨髓瘤的效果优于单纯MP方案和自体干细胞移植 [Abstract No: 1]	报告人： T Facon
2:15 PM - 2:30 PM	Discussion 讨论
2:30 PM - 2:35 PM	Question and Answer 提问与解答
2:35 PM - 2:50 PM	Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. KIT酪胺酸激酶(TK)基因突变可以预测成人核心结合因子白血病(CBF-AML)的复发：癌症和白血病B小组的研究 [Abstract No: 2]	报告人： Peter Paschka, MD
2:50 PM - 3:05 PM	Discussion 讨论
3:05 PM - 3:10 PM	Question and Answer 提问与解答
3:10 PM - 3:25 PM	Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) SU11248和干扰素α联合一线解救治疗转移性肾癌的III期随机临床试验 [Abstract No: LBA3]	报告人： Robert John Motzer, MD
3:25 PM - 3:40 PM	A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma temsirolimus (TEMSR)、干扰素α和TEMSR+干扰素α三组一线解救预后不良的进展期肾癌的III期随机对照研究 [Abstract No: LBA4]	报告人： Gary R. Hudes, MD
3:40 PM - 3:55 PM	Discussion 讨论
3:55 PM - 4:00 PM	Question and Answer 提问与解答

(彭俊杰编译；吴世凯审校)